Roche BETs on Tensha

Roche (SIX:ROG; OTCQX:RHHBY) will acquire Tensha Therapeutics Inc. (Cambridge, Mass.) for $115 million in cash up front. Tensha shareholders are eligible for $420 million in milestones.

The pharma will gain Tensha's TEN-010, a small molecule inhibitor of bromodomains of the bromodomain and extra-terminal domain (BET) family of proteins, including bromodomain containing 4 ( BRD4), BRD3, BRD2 and testis-specific bromodomain ( BRDT). The compound is in a pair of Phase Ib trials: one in solid tumors, including NUT midline carcinoma (NMC); and one in acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). ...